Biotech VC Funds

Perot Jain is a Dallas-based early-stage venture capital firm co-founded by Ross Perot Jr. and Anurag Jain in 2014. The firm primarily focuses on investing in innovative and disruptive startups within the healthcare, mobility, business services, and tech-enabled B2B sectors. Notable investments include companies like Access Healthcare, specializing in healthcare IT solutions, and Worlds, which creates AI-generated models for business process optimization. Other significant portfolio companies are Spacee, which offers virtual store walkthroughs, and Booster, a mobile fuel delivery service. Perot Jain typically invests up to $500,000 in seed and Series A rounds, aiming to support scalable businesses located in the United States. The firm leverages its extensive network and operational expertise to provide more than just capital, offering strategic guidance and resources to help startups achieve transformational growth. The team at Perot Jain includes a mix of founders, executives, and industry experts who work closely with entrepreneurs to drive innovation and impact. The firm has made over 70 investments and maintains a strong presence in the North Texas startup ecosystem, contributing to the region's growth as a national center for technology and innovation.

Petri Bio is a biotechnology company focused on developing next-generation therapeutics derived from gut microbes. The company leverages the vast genetic information within the microbiome to discover and develop novel treatments for challenging diseases such as inflammatory bowel disease (IBD) and fatty liver disease. These diseases often have limited effective treatments, making Petri Bio's work particularly impactful. Founded by Shu Li, a Ph.D. in plant biology, and Joseph Schinaman, a biomedical researcher, Petri Bio is committed to using microbial compounds to create new medicines. Their approach involves mining microbial genomes for peptides with therapeutic potential, which they believe could lead to breakthroughs in treating various conditions that are currently underserved by existing pharmaceutical solutions. Petri Bio has also been involved in the development of treatments related to COVID-19, using their platform to identify compounds that could potentially neutralize the virus. Their work has garnered attention and interest from major pharmaceutical companies, and they continue to expand their pipeline to include other critical areas of healthcare.

Pfizer Venture Investments (Pfizer Ventures) is the corporate venture capital arm of Pfizer Inc., established in 2004 and headquartered in New York. The platform carries a $900 million total capital commitment, including a $600 million top-up announced in Q4 2021, and backs private companies at all stages of development with a strong bias toward early-stage therapeutics and platform technologies. Investment priorities mirror Pfizer's therapeutic areas: inflammation and immunology, internal medicine, oncology, and neuroscience, extending into platform technologies, diagnostics, drug delivery, pharmaceutical services, and healthcare IT. Roughly 25 percent of available capital, approximately $150 million, is explicitly earmarked for early-stage neuroscience investments. Across approximately 200 investments, Pfizer Ventures has built a concentrated neuroscience portfolio including Aquinnah, Autifony, Cortexyme, MindImmune, Mission Therapeutics, and Neuronetics. The platform leads rounds and invests globally, though deployments skew toward US-based companies. Recent notable investments include Curve Therapeutics (GBP 40.5 million Series A, led in February 2024), Enara Bio ($32.5 million Series B co-led with M Ventures in October 2024), Enlaza Therapeutics ($100 million Series A syndicate in September 2024), OTR Therapeutics ($100 million Series A for a Chinese biotech in June 2025), and Crossbow Therapeutics in March 2026 as the most recent disclosed investment. Pfizer Ventures serves as a strategic window on early-stage innovation across life sciences globally. Portfolio companies benefit not only from capital but also from Pfizer's regulatory expertise, clinical development networks, and therapeutic-area know-how, creating pathways to partnership, licensing, and acquisition that financial-only investors cannot offer.

Phoenix Venture Partners (PVP) is a Silicon Valley-based venture capital firm founded in 2009 and headquartered in San Mateo, California, with satellite offices in Singapore and Cambridge, Massachusetts. The firm specializes in taking transformative hard-technology innovations in advanced materials, novel devices, innovative manufacturing processes, and state-of-the-art tools from proof-of-concept to commercialization. Founder and Managing General Partner John Chen leads a team of seven, including five partners. PVP's core thesis targets what the firm calls Convergent Tech: the intersection of advanced materials, biology, and hardware with advanced computation and AI, investing in early-to-revenue-stage companies tackling pain points in computing, electronics, transportation, energy, industrial applications, and life sciences. Typical checks range from $100,000 to $7.5 million, and the firm leads Series A rounds. Over its 19-year history, PVP has made 85 investments, averaging two new investments per year in the last decade, and has recorded 3 IPOs and 17 acquisitions. Notable portfolio outcomes include AbSci (PVP led the 2016 Series A; AbSci listed on NASDAQ in July 2021 at a $1.45 billion market cap), NBD Nanotechnologies, and COTSWORKS (exited in July 2025). Recent investments include UbiQD (Series B-II in February 2026 as the most recent disclosed investment), Qolab (superconducting quantum computing), ORAN Development, and Nanofiber Quantum Technologies. Phoenix Venture Partners provides founders with hands-on support in business development, IP strategy, recruitment, and exit planning, leveraging a global network of strategic partners spanning manufacturing, government, and enterprise markets. Its specialist positioning in hard tech and advanced materials makes it one of the few firms capable of leading early institutional rounds in deep-science companies that require both technical diligence and long commercialization timelines.

Phyto Partners is a venture capital firm based in Boca Raton, Florida, focused on the cannabis industry. Since its founding in 2015, the firm has invested in around 30 companies across the cannabis value chain. Their strategy prioritizes ancillary businesses, which provide essential solutions to support licensed operators, such as advertising technology, agricultural innovations, biotechnology, SaaS, and medical dosing technology. Phyto Partners takes an active role beyond just providing capital, offering strategic support, networking, and business development assistance to help their portfolio companies grow. Their investments span various sectors, including branded products, cannabis delivery services, and data analytics. The firm is known for helping companies navigate the highly regulated cannabis market, seeing compliance and technology solutions as key growth areas. In addition to their cannabis focus, Phyto Partners has expanded into brain health and psychedelics with their "Phyto Psyche" fund, recognizing the growing interest in neurowellness and mental health treatments.

Pi Campus is a venture capital firm based in Rome, Italy, that specializes in investing in early-stage startups focused on artificial intelligence (AI) and tech innovations. Founded by Marco Trombetti, Isabelle Andrieu, and Gianluca Granero, Pi Campus originated from Translated, a pioneering AI-driven translation service. The firm primarily invests in startups that apply AI to disrupt traditional industries, especially those perceived as slow-moving, and supports them with funding, mentorship, and access to a vast international network. Pi Campus typically invests between €50,000 and €500,000 in exchange for equity stakes of 1% to 10%, targeting startups in Europe and the U.S. with a strong focus on AI applications. Their portfolio includes companies like Boom Supersonic, which is working on sustainable supersonic travel, and Skymind, an AI ecosystem builder. In addition to financial investment, Pi Campus provides a nurturing environment for startups, including workspace in luxury villas converted into offices, and mentorship through their School of AI, which trains engineers on real-world problems with the support of global tech leaders like Google and Facebook. Pi Campus places a significant emphasis on fostering innovation and diversity, offering a collaborative platform for AI enthusiasts and entrepreneurs who combine design, technology, and emotional intelligence to create impactful products​.

Pi Ventures, founded in 2016 and based in Bengaluru, India, is a venture capital firm focused on early-stage investments in deep tech startups. The firm specializes in sectors such as artificial intelligence, machine learning, the Internet of Things (IoT), and healthcare. Notable investments by Pi Ventures include companies like Agnikul, an aerospace startup; SwitchOn, which focuses on industrial automation and machine learning; and Zero Cow Factory, a biotech company developing sustainable food products. Pi Ventures has invested in a total of 42 companies and has made significant exits, including Zenatix Solutions through a merger and acquisition. The firm was founded by Manish Singhal and Umakant Soni, and the leadership team includes Managing Directors Roopan Aulakh and Shubham Sandeep. Pi Ventures is known for backing innovative startups and supporting them through their growth phases with a combination of capital and strategic guidance.

Picus Capital, founded in 2015 and headquartered in Munich, Germany, is an early-stage venture capital firm with a long-term investment philosophy. The firm focuses on technology-driven sectors such as financial services, HR, energy & climate, healthcare, logistics & mobility, real estate & construction, crypto & web3, deep tech, and e-commerce. Picus Capital has made significant investments in companies like Ledge, Spot My Energy, Cove Living, Poolit, and Alasco, among others. Their portfolio spans across 20+ countries with a diverse range of startups that are innovating in their respective fields. The firm's unique approach emphasizes close partnerships with their portfolio companies, assisting them with strategic decisions and operational challenges. With offices in Munich, London, New York, Beijing, and other key locations, Picus Capital is well-positioned to support global growth and expansion. The firm is led by co-founders Robin Godenrath, Alexander Samwer, and Jeremias Heinrich, who bring extensive experience and a strong entrepreneurial mindset to the table. Their team is dedicated to helping daring technology companies build successful, global enterprises that challenge the status quo and shape the future​

Pillar VC is a venture capital firm based in Boston, Massachusetts, specializing in early-stage investments, particularly in pre-seed and seed rounds. Founded in 2016, the firm focuses on supporting founders from the very beginning, often before formal incorporation, and invests in various sectors including AI/ML, biotech, consumer, enterprise, fintech, and crypto/web3. Pillar VC manages multiple funds, including the recent $192 million raised for Pillar III and Pillar Select. This allows them to continue backing companies with significant potential to become foundational pillars of their industries. Their investment strategy includes leading seed rounds with investments ranging from $2 million to $6 million and making pre-seed investments between $50,000 and $500,000. The firm is distinguished by its commitment to buying common stock to align closely with the founders' interests. Pillar VC also provides robust support through a dedicated platform team that assists with talent acquisition, expert connections, pitch polishing, and investor introductions. This approach has helped foster successful companies like Algorand, Desktop Metal, and PillPack​.

Pioneer Fund, founded in 2017, is a venture capital firm based in San Francisco, CA, and Toronto, Canada. This unique fund is driven by over 400 Y Combinator alumni, focusing on investing in top startups that emerge from the Y Combinator accelerator. With a strong emphasis on early-stage investments, Pioneer Fund supports a diverse range of industries, including consumer products, financial services, AI, life sciences, and education technology. Notable investments by Pioneer Fund include companies like Aspire, C16 Biosciences, Curebase, Dover, and OnDeck, reflecting their broad and impactful portfolio. The fund has made over 600 investments and continues to actively support new ventures, emphasizing their commitment to fostering innovation and growth in the startup ecosystem. Pioneer Fund operates with a flexible and founder-friendly approach, often providing quick investment decisions. They also maintain a global investment perspective, with a presence in countries such as India, Nigeria, Argentina, and Chile. This geographical diversity enables them to back startups with international ambitions and scalability. The team at Pioneer Fund is led by founder Daniel Gross, along with other notable members such as Tim Suzman and Rajiv Bhat. They bring a wealth of experience and connections, leveraging their backgrounds as Y Combinator alumni to provide valuable mentorship and support to portfolio companies.

Pirveli Ventures is a Montreal-based family fund that focuses on early-stage investments, particularly in Israeli startups. The fund is known for its laid-back, hands-on approach, providing both initial and follow-on investments while actively supporting portfolio companies in areas like strategy, business development, and management. This close involvement allows Pirveli to act as an extension of the startup teams they back. Their investments typically center around sectors such as agricultural tech, health tech, sustainability, and automotive technologies. Notable companies in their portfolio include Gordian Surgical, Eco Wave Power, and Flora Fotonica, reflecting a commitment to innovative, high-impact ventures. Pirveli Ventures generally invests in the seed stage, and while they do not limit themselves to a specific check size, they are comfortable co-investing alongside other funds. Their investment philosophy focuses on working with startups that have a clear business plan and strong management teams, helping them transition from innovative ideas to successful companies​.

Pitango Venture Capital, established in 1993 and based in Herzliya, Israel, is one of the largest and most prominent venture capital firms in Israel, managing over $3 billion across various funds. The firm focuses on investing in early-stage startups through Pitango First, growth-stage companies through Pitango Growth, and health tech innovations through Pitango HealthTech. Pitango has backed a range of notable companies that have become leaders in their respective fields. These include Via Transportation, which has revolutionized urban mobility, Taboola, a significant player in content recommendation and discovery, and Varonis Systems, a cybersecurity company. The firm has also been involved in successful exits, such as the acquisition of Anobit by Apple and the IPO of Radware on NASDAQ. The investment strategy of Pitango emphasizes partnering with visionary entrepreneurs and providing them with the necessary resources and guidance to scale their businesses. The team at Pitango includes experienced professionals like Nechemia (Chemi) Peres and Rami Kalish, who bring a wealth of expertise to the firm’s diverse investment portfolio. Pitango's approach is characterized by a strong commitment to innovation and sustainability, ensuring that the companies they invest in are not only successful but also contribute positively to the broader community. This dedication has positioned Pitango as a key player in both the Israeli and global venture capital ecosystems.

Piva Capital is a San Francisco-based venture capital firm, launched in 2019, that targets transformative companies at the intersection of energy, mobility, advanced manufacturing, and new materials. They focus on early to growth-stage startups with breakthrough technologies that address pressing global challenges. Piva backs innovators in fields such as decarbonization, industrial automation, and sustainable production, seeking companies with scalable, cross-industry applications. Some of their notable investments include Boston Metal (decarbonizing steel), Velo3D (revolutionizing additive manufacturing), and Koloma (geologic hydrogen production). Piva’s portfolio is heavily concentrated in North America and Europe, where they partner with visionary entrepreneurs to advance impactful industrial solutions. Piva typically writes large checks, leading rounds and bringing a deep network of industry contacts to help their portfolio companies scale quickly. They are also known for their ESG (Environmental, Social, and Governance) initiatives, embedding sustainability into their investment strategy. The leadership team includes experts like CEO Ricardo Angel and Managing Partner Mark Gudiksen, both based in San Francisco, who bring decades of experience in energy, materials, and industrial sectors​.

Planet A Ventures, based in Berlin, is a pioneering venture capital fund dedicated to supporting GreenTech startups that drive significant environmental impact. With a first fund of €160 million, Planet A invests primarily in European companies focused on achieving net-zero emissions and promoting sustainability across various sectors including agriculture, energy, manufacturing, and transportation. Notable investments include Makersite, which uses AI to enhance sustainable supply chains, and INERATEC, known for its modular chemical plants producing sustainable fuels. The fund also backs innovative solutions like Wildplastic, which recycles plastic waste, and GA Drilling, which develops geothermal energy technologies. Planet A takes a science-based approach to investing, incorporating life cycle assessments into its due diligence process to ensure each investment's positive impact. This methodology allows their in-house science team to veto investments that don't meet stringent environmental criteria. The fund typically writes initial checks ranging from €500k to €3 million and prefers to lead rounds. Key team members include founders Tobias Seikel, Nick de la Forge, Fridtjof Detzner, Christian Schad, Christoph Gras, and Lena Thiede. Their combined expertise spans investing, entrepreneurship, and environmental science, ensuring a well-rounded support system for portfolio companies. Active engagement with portfolio startups and a commitment to scalable, impactful solutions position Planet A Ventures as a leader in the GreenTech VC space.

Playfair Capital is a London-based venture capital firm that takes a contrarian approach to pre-seed investing. Unlike many high-volume funds, Playfair focuses on making a limited number of high-conviction investments—around 6 to 8 per year—allowing the team to dedicate significant time and resources to each portfolio company. With a sector-agnostic strategy, Playfair invests across various industries, backing visionary founders who are reimagining the future. Notable investments include companies like Thought Machine, Andela, and Mapillary, highlighting Playfair's ability to identify disruptive technology startups with the potential to scale globally. The firm operates primarily in the UK and Europe but maintains a global mindset, focusing on transformative technologies and business models. Playfair’s investment philosophy extends beyond financial capital. The team, which includes a diverse mix of professionals from angel investors to engineers, provides operational and strategic support to help startups grow rapidly. This approach has contributed to the success of over 70 companies across its two funds, with 73% of their startups securing Series A funding. The firm is also deeply committed to diversity, as evidenced by its Female Founder Office Hours initiative, which has helped raise £600 million for female-led startups. Led by Managing Partner Chris Smith and Founding Partner Federico Pirzio-Biroli, Playfair remains dedicated to building long-term relationships with founders, fostering an inclusive and collaborative venture ecosystem.

Playground Global is an early-stage venture capital firm based in Palo Alto, California, specializing in deep-tech investments. Founded in 2015 by Andy Rubin, Peter Barrett, Matt Hershenson, and Bruce Leak, the firm focuses on transformative technologies that promise to define new industry standards and create entirely new markets. Playground Global's investment strategy targets Seed and Series A companies, with initial investments ranging from $1 million to $20 million. Their portfolio includes companies in next-gen computing, logistics, automation, infrastructure, decarbonization, and engineered biology. The firm recently closed its third fund with $410 million in new capital, bringing its total assets under management to over $1.2 billion. This fund continues Playground's commitment to investing in ambitious founders and groundbreaking technologies. Some notable investments from Fund III include d-Matrix, Ideon Technologies, Amber Bio, Infinimmune, and Atomic AI​. Playground Global supports its portfolio companies not just with capital but also with deep technical and operational expertise. The team, comprising over 40 members, includes many with strong technical backgrounds, ensuring comprehensive support in areas such as engineering, product development, business development, and marketing.

Plexo Capital is a venture capital firm founded in 2018 by Lo Toney, a former partner at Google Ventures (GV). The firm operates on a unique hybrid model, investing both in emerging venture capital funds and directly in early-stage startups, particularly those led by women and people of color. This strategy allows Plexo to tap into a broader and more diverse deal flow, aiming to generate superior returns while increasing diversity within the venture ecosystem. Plexo Capital manages a $42.5 million fund, with investments from prominent backers like Alphabet, Intel Capital, Cisco Investments, and the Ford Foundation. The firm typically invests $500,000 to $5 million in venture funds and $500,000 to $2 million directly in startups. Some of the notable companies in their portfolio include Blavity, PlayVS, and Wrapbook, a payroll management software company that has since become a unicorn. Plexo’s approach is deeply rooted in the belief that diverse perspectives lead to better investment outcomes, particularly at the seed stage where non-traditional networks can provide unique insights. The firm also emphasizes supporting its portfolio companies by leveraging its extensive network of strategic partners and experts in growth, product development, and customer acquisition. Plexo Capital is based in San Francisco but operates globally, with investments spanning across North America, Africa, and Latin America

Plum Alley is a New York-based venture capital firm founded in 2012 by Deborah Jackson and Andrea Moffitt. The firm focuses on investing in early-stage, high-growth technology and healthcare companies, particularly those with at least one female founder from the STEM fields. Their portfolio includes companies like AiFi, which specializes in autonomous checkout technology, and Gameto, a biotechnology company addressing ovarian aging. Plum Alley has a strong emphasis on supporting companies that tackle significant human and environmental challenges using advanced technology. They have invested nearly $80 million across 32 companies through member investors and their Venture Fund I. Their investment strategy includes offering membership opportunities for investors to engage with curated investment opportunities and targeted venture funds focused on specific sectors​​. The firm has made notable exits, including companies like Shine, Node, and Tinkergarten. They also have a robust portfolio of ongoing investments in sectors such as digital health, smart hardware, and automation.

Plus Venture Capital (+VC) is a leading venture capital firm that focuses on early-stage tech and tech-enabled startups in the MENA region and its diaspora. Established with a deep understanding of the region's entrepreneurial landscape, +VC is known for being founder-centric, offering both seed and follow-on investments up to Series A. The firm typically makes initial investments around $100K at the seed stage, with follow-ons reaching up to $1M for top-performing companies. +VC stands out with its proactive and fast approach, helping startups navigate critical early stages by providing not just capital but also operational guidance and strategic support. They are committed to promoting diversity and inclusion, with a notable percentage of their portfolio companies having at least one female founder. Their investment portfolio spans multiple sectors, including fintech, consumer tech, and enterprise applications, with investments in countries like the UAE, Egypt, and Kuwait. With over 200 transactions under their belt, +VC takes pride in being the first institutional money for many startups and continues to support them through to exits. The firm also emphasizes community building, offering programs like +Growth, which provide startups access to mentorship, resources, and a network of other founders. By leveraging their global networks and roots in Silicon Valley, +VC ensures that founders get the best chance to scale their businesses globally.

PMV (Participatie Maatschappij Vlaanderen) is an independent investment company owned by the Flemish government, focused on building a sustainable economy in Flanders. Founded in 2001, PMV provides a wide range of financial solutions, including capital, loans, and guarantees, to support ambitious companies and projects that deliver both social impact and financial returns. Their investment activities span across various sectors, including clean tech, life sciences, real estate, and infrastructure, with a particular emphasis on projects that drive digital and green transitions. PMV manages a significant portfolio of assets, approximately €1.7 billion, and operates a variety of funds aimed at different stages of business growth and types of projects. They are actively involved in both direct investments and fund management, often collaborating with private and public partners to maximize impact. Additionally, PMV is a key player in initiatives like the InvestEU program, which aims to mobilize large-scale investments in sustainable infrastructure and other strategic areas across Belgium and Europe. This partnership reflects PMV's commitment to supporting projects that contribute to the European Union's green and digital goals.

oint72 Ventures is a global venture capital firm founded by Steven A. Cohen in 2016. Based in New York, Seattle, and San Francisco, Point72 Ventures focuses on fintech, artificial intelligence, and enterprise technology sectors. The firm leverages Point72 Ventures is a global venture capital firm founded by Steven A. Cohen in 2016. Based in New York, Seattle, and San Francisco, Point72 Ventures focuses on fintech, artificial intelligence, and enterprise technology sectors. The firm's investment strategy involves thorough research and a deep understanding of industries. Point72 Ventures writes checks from $250k to $50 million, from pre-seed to pre-IPO rounds. They often lead investment rounds and take board seats to support their portfolio companies. Point72 Ventures has a diverse portfolio including Apex, Tektonic AI, and DriveWealth. The team includes experts like Adam Carson, focusing on fintech and crypto, and Pete Casella, a senior advisor with a strong fintech background. Point72 Ventures engages with passionate founders who are deeply knowledgeable about their industries, emphasizing data and thorough analysis in their investment process. They seek companies with clear potential for innovation and growth.

Polaris Partners, a venture capital firm established in 1996 and headquartered in Boston, Massachusetts, has a distinguished history of investing in transformative healthcare and biotechnology companies. With over 400 companies funded, more than 100 exits, and 50 IPOs, Polaris Partners has solidified its position as a leading investor in the industry​​. The firm's portfolio is diverse, including notable companies such as Ironwood Pharmaceuticals, JibJab Media, LegalZoom, and Living Proof. Polaris Partners focuses primarily on healthcare, life sciences, and biotechnology sectors, targeting innovative care delivery models, digital health solutions, patient and provider platforms, and data science and analytics​ ​. Polaris Partners operates multiple funds, including the Polaris Growth Fund, which supports the expansion of profitable, founder-owned technology companies, and the Polaris Innovation Fund, aimed at accelerating the commercial and therapeutic potential of early-stage academic research​​. Key team members include Brian Chee, Bryce Youngren, and Alexandra Cantley, who bring extensive expertise and leadership to the firm's investment strategies. Polaris Partners prides itself on being more than just investors—they are builders and connectors with a deep network of syndicate partners, universities, and research institutions​​. For entrepreneurs, Polaris Partners offers robust support, leveraging their decades of experience and comprehensive network to help companies achieve successful outcomes and bring innovative therapies to market.

Pontifax Venture Capital is a healthcare-focused venture capital firm based in Herzliya, Israel, founded in 2004. The firm manages approximately $1.2 billion across multiple funds and focuses on identifying and investing in transformative life sciences technologies at all stages of development. Pontifax's portfolio includes around 100 companies that address significant unmet medical needs through groundbreaking innovations​. The firm was co-founded by Eli Hurvitz, a legendary figure in the pharmaceutical industry and former CEO of Teva Pharmaceuticals, alongside Ran Nussbaum and Tomer Kariv. Pontifax takes a hands-on approach with its portfolio companies, providing strategic guidance and leveraging extensive networks to help these companies grow and succeed. Pontifax's investment strategy spans various sectors within the life sciences, including biopharmaceuticals, medical devices, and gene therapy. Notable investments include Kite Pharma, which was acquired by Gilead Sciences, and Eloxx Pharmaceuticals, which focuses on treatments for genetic diseases caused by nonsense mutations.

Pool Global Partners is a venture capital firm that focuses on investing in high-growth technology companies, with an emphasis on sectors such as healthcare, software development, and biotechnology. Founded in 2016 and based in Toronto, Pool Global Partners aims to back innovative startups that leverage deep technology to create transformative solutions. The firm operates with an outcome-driven approach, providing both financial capital and strategic support to help startups scale efficiently. Pool Global Partners’ portfolio includes investments in companies like modl.ai, an AI gaming startup, Prescryptive Health, a healthcare technology company, and Acorn Biolabs, a biotechnology firm. The firm’s investment strategy is centered around early-stage ventures, particularly in seed and Series A rounds, with an average deal size of around $1 million. With a global presence, Pool Global Partners actively collaborates with other venture firms such as Saltagen Ventures and PreSeed Ventures, co-investing in high-potential startups across North America and Europe. Their goal is to support technological innovation that addresses critical challenges, particularly in sectors that are poised for significant growth.

Portal Innovations is a Chicago-based venture development engine that specializes in supporting early-stage life sciences, medtech, and bioinformatics startups. Founded by John Flavin, a seasoned entrepreneur with a strong track record in life sciences, Portal Innovations provides what it calls "Crafted Capital™," which includes seed funding, state-of-the-art lab space, and strategic management support. The firm operates in key U.S. biotech hubs, including Chicago, Atlanta, Boston, and Houston, offering over 80,000 square feet of lab and office space tailored to the needs of its portfolio companies. Portal Innovations has a unique approach that bridges scientific ideation through commercial proof of concept by leveraging strong ties with academic institutions and industry partners. This enables them to identify and nurture promising startups, particularly those emerging from university labs. Portal Innovations' portfolio includes a diverse range of companies such as Cardiosense, which is developing a digital biomarker platform, and ClostraBio, focused on new therapeutics for inflammatory bowel disease and food allergies. The firm’s recent expansion into Houston, in collaboration with the Texas Medical Center, highlights its commitment to growing the U.S. life sciences ecosystem by providing critical resources and support to early-stage companies​.

Portugal Ventures, founded in 2012, is a prominent venture capital firm in Portugal that focuses on early-stage investments. As part of the Portuguese promotional bank Grupo Banco Português de Fomento, Portugal Ventures aims to boost the country's entrepreneurial ecosystem by providing financial and strategic support to innovative startups. The firm has invested over €214.8 million since its inception, managing a diverse portfolio that spans various sectors, including technology, life sciences, and tourism. Notable investments include Farfetch, Principle Power, and Fyde. In 2022, Portugal Ventures invested €18.6 million in 42 startups, highlighting its commitment to fostering innovation despite economic uncertainties​. Portugal Ventures operates several investment initiatives such as Call INNOV-ID, which targets early-stage startups with developed technology but still in prototype or proof-of-concept phases. This initiative, in partnership with the National Innovation Agency, has seen significant success, investing €5.5 million in 55 startups across three editions. Other initiatives include Call Tourism and Call FIT, aimed at promoting innovation in tourism and fostering new technologies. The firm emphasizes co-investments and partnerships to strengthen its portfolio companies. In 2022, it made follow-on investments totaling €9.8 million in 25 companies, ensuring they have the capital to scale and thrive. Notable follow-on investments include Aptoide, Probely, and Didimo​

POSCO Venture Capital — operating as POSCO Investment and POSCO Capital — is the corporate venture capital arm of POSCO Holdings, the Seoul-based Korean steel and industrial conglomerate. Founded in 1997 and headquartered in Seoul, South Korea, POSCO Investment is a dedicated venture-investment and fund-management specialist within the POSCO group, with a mandate to support core strategic, adjacent, and future-growth priorities. The firm deploys capital through three structures: Holdings CVC (balance sheet investing), Collaborative CVC (fund-of-funds and co-investments), and Principal Investment direct deals. POSCO's investment thesis concentrates on startups whose core technologies align with the group's future-growth strategy — including digital transformation, clean hydrogen, advanced carbon materials, renewable energy, biohealth, autonomous driving and AI, robotics, lithium-ion energy materials, agri-tech, SMR nuclear, and IoT. POSCO Capital acts as GP on a KRW 80 billion (~$59 million) CVC fund — the largest such fund POSCO Holdings has independently committed to — alongside a KRW 50 billion (~$35 million) VC vehicle. The firm has also built the Change Up Ground venture incubation complex (a KRW 83 billion investment that opened in July 2021). Across its history, POSCO Capital has made 155 investments and produced 20 portfolio exits, including Craver (exit September 2024) and H Energy (Series C, October 2024). POSCO Venture Capital's industrial heritage gives it a distinctive edge in deep-technology sectors that sit at the intersection of materials science, energy transition, and advanced manufacturing. Portfolio companies benefit from direct connections to POSCO Holdings' global supply chain, manufacturing facilities, and corporate R&D capabilities, accelerating commercial development timelines in ways that purely financial sponsors cannot replicate.

Position Ventures is an early-stage VC firm focused on helping startups sharpen their positioning and communications strategies. Founded by Jenny He, an experienced communications strategist, the firm prides itself on being a strategic partner that helps founders craft compelling narratives to cut through the noise. Position Ventures has backed notable companies like Twitch, Snapcommerce, Sleeper, and WorkWhile, with a particular interest in tech-driven startups across sectors like media, e-commerce, and software. Their strategy goes beyond just funding—they offer hands-on support with media relations, internal communication, and public launches. Founders often credit Jenny and her team for providing invaluable help in media training, securing coverage, and preparing for high-stakes launches. Position Ventures primarily invests in U.S.-based startups but takes a founder-centric approach, actively working alongside teams to refine their market positioning. They seek startups with clear storytelling potential and strong founder-market fit. The firm tends to participate in early-stage rounds, often providing lead investments with strategic support, though they don’t disclose average check sizes. Position Ventures prefers to be approached by founders who are clear on their brand's positioning and growth potential, favoring businesses that aim to stand out through effective narrative and media strategies.

Possible Ventures is an innovative venture capital firm based in Munich, Germany, dedicated to backing mission-driven teams using frontier technology to address significant global challenges. Founded by Chris Hitchen, who brings extensive experience from previous roles at EQT Ventures and Project A, the firm focuses on early-stage investments, particularly at the pre-seed and seed stages. The fund's investment strategy is centered on deep tech and techbio sectors, including AI, life sciences, climate tech, energy, cybersecurity, space tech, and dual-use technologies. Notable investments from their portfolio include successful companies like Sorare, Anydesk, Immutable, Cognigy, and Holidu, alongside deep tech innovators such as Marvel Fusion and ToZero. Possible Ventures typically writes checks ranging from €250k to €500k and often co-invests with a global network of over 200 entrepreneurial investors and 250 founders. Their approach involves a high level of engagement and support, providing startups not only with capital but also with strategic advice and connections to other value-added investors. The team at Possible Ventures includes key figures such as Dr. Christoph Baumeister, Marie Tai, and Thyra Seitz, who bring diverse expertise across various high-tech and bio-scientific fields. They prefer founders to approach them with clear, impactful technology solutions that align with their mission of solving humanity's biggest challenges. Possible Ventures has made a significant mark by maintaining a strong presence in both European and global markets, offering a robust support system for early-stage startups aiming to make a substantial impact.

Practica Capital is an early-stage venture capital firm dedicated to supporting Baltic founders in Lithuania, Latvia, and Estonia. With over €130 million in assets under management, Practica Capital focuses on investing in tech-driven companies at the seed, pre-seed, and Series A stages. Their portfolio includes notable startups like TransferGo, Eneba, CGTrader, and Trafi. The firm's investment strategy is characterized by active involvement in their portfolio companies, providing strategic guidance and leveraging a strong network of co-investors, including local and international VCs, accelerators, and angel investors. Practica Capital typically invests between €300k and €3M per round, aiming to partner with founders who exhibit strong ambition and innovative potential. The team at Practica Capital includes experienced professionals like Donatas Keras, Tomas Andriuškevičius, and Arvydas Bložė, who bring valuable industry insights and entrepreneurial experience to the table. For startups seeking investment, Practica Capital values clear, compelling pitches that demonstrate significant market potential and technological innovation. Their approach as an entrepreneurial and active investor positions them as a key player in the Baltic venture ecosystem, helping to drive the growth and success of tech startups in the region.

Praetura Ventures, founded in 2011 and based in Manchester, UK, is a venture capital firm that emphasizes offering "more than money" to early-stage businesses. Their focus is on supporting high-growth companies across various sectors including medtech, transport tech, retail tech, insurtech, and SaaS. Notable investments in their portfolio include ScubaTx, Seatfrog, Sparkbox, and Sprout AI, which span diverse industries from medical technology to AI-driven retail solutions. Praetura Ventures typically invests around £1.9 million per company and has £544 million in assets under management. Their approach involves not only providing capital but also offering strategic support through their operational partners who have extensive industry experience. This holistic support model helps startups navigate growth challenges effectively. The firm's leadership team includes co-founders David Foreman and Peadar O'Reilly, along with partners like Jonathan Prescott and Sam McArthur, who bring decades of experience in financial services and investment management. For entrepreneurs, Praetura Ventures values clear communication and innovative solutions that address significant market needs. Praetura Ventures is particularly active in the Northern UK region, supporting local startups and helping them scale through both capital investment and strategic guidance. They maintain a strong network of co-investors and partners to maximize the growth potential of their portfolio companies.

PrairieGold Venture Partners (PGVP) is an early-stage venture capital firm founded in 2003 and headquartered in Sioux Falls, South Dakota — one of the few established institutional VCs based in the Upper Midwest of the United States. The firm invests in life sciences, information technology, and energy and greentech companies, with a deliberate focus on Midwestern opportunities that allows it to take meaningful ownership positions with relatively modest capital commitments and play an active hands-on role in company strategy. Thematic priorities include early cancer detection, renewable energy, advanced surgical technologies, and differentiated agricultural and industrial biotechnology. PGVP operates multiple funds including PrairieGold Venture Capital Fund II LP and related Growth Capital Annex vehicles, and leads rounds at Series A and Series B. It typically provides follow-on capital across the life of its portfolio companies. The firm has disclosed approximately 14 portfolio investments; notable names include Virtual Incision (PGVP led its $30 million Series C alongside cultivate(MD) and InVivium Capital in September 2023), Agrivida (agricultural biotech and animal nutrition), Zea2 (bio-based commodity chemicals), and Lineagen (diagnostics). PGVP's team of 11 to 50 professionals combines venture capital, investment banking, legal, government, university, public relations, and industry operating experience. PGVP's regional positioning is both its thesis and its competitive advantage: by concentrating on the Midwest, the firm accesses exceptional science and engineering talent at earlier stages and lower valuations than coastal-based investors typically encounter. Its active management style and willingness to lead translates to genuine governance weight and the ability to help portfolio companies recruit executives, navigate regulatory pathways, and build strategic partnerships with regional industrial and academic anchors.

Predictive Venture Partners is a venture capital firm founded in 2019, specializing in early- and growth-stage investments in startups that leverage data-driven and predictive technologies. Based in North Andover, Massachusetts, Predictive VC focuses on sectors like artificial intelligence, fintech, analytics, and enterprise applications. The firm is highly selective, typically targeting innovative startups that demonstrate strong potential for scalability and societal impact. Predictive VC’s portfolio includes investments in companies like Mighty Health, a healthcare platform, and Pomelo, a financial software company. The firm often co-invests with other well-known funds, such as Insight Partners and Pareto Holdings, and has a growing track record of supporting companies from seed to later stages. They are particularly interested in ventures that harness data to create efficiencies and solve complex problems across industries like financial services, logistics, and digital health. The firm is led by Kevin Fung, who brings deep expertise in tech-driven investments. Predictive VC’s investment strategy emphasizes building long-term partnerships with founders, providing both capital and operational expertise to help startups scale. Although primarily focused on the U.S. market, the firm also invests in international startups with high growth potential. For startups seeking to engage with Predictive VC, demonstrating a strong market fit, a robust tech platform, and clear paths for growth is key to gaining attention.

Preface Ventures, founded in 2020 and headquartered in New York, focuses on early-stage investments in enterprise infrastructure and software startups. Preface Ventures typically invests between $500k to $2M in pre-seed and seed rounds, with follow-on investments ranging from $1M to $3M. They are known for being the first check in 80% of their investments, and often invest before companies even have a bank account​. Notable investments in their portfolio include companies like Leen, Knock, and Qpoint, reflecting their focus on network management and business productivity software. Preface Ventures has also seen successful exits with companies like Truebill and Remitly. The firm is led by Founder and General Partner Farooq Abbasi, who emphasizes a hands-on approach in the first 100 days of investment, helping startups build financial and board reporting infrastructure. Preface Ventures also assists in constructing seed syndicates, making key customer introductions, and supporting team building efforts​. By leveraging deep industry relationships and a focus on strategic support, Preface Ventures aims to help founders build enduring companies at the frontier of enterprise innovation.

Prelude Ventures, headquartered in San Francisco, is a leading venture capital firm focusing on climate tech investments. Since its inception in 2013, the fund has backed over 150 companies, emphasizing innovative solutions for carbon reduction and sustainability. Notable investments include QuantumScape, a leader in solid-state battery technology; Planet Labs, a satellite imagery provider; and Benson Hill, specializing in plant-based food ingredients. Prelude Ventures concentrates primarily on energy, food, agriculture, and resource optimization sectors, with a geographic focus predominantly in North America. Their investment strategy targets early to growth-stage companies that have the potential to significantly impact climate change. They prefer leading rounds and often provide substantial follow-on funding to support scaling. The fund’s average check size varies, typically ranging from $1M to $20M, depending on the stage and needs of the company. Prelude Ventures is known for being active and engaged investors, offering strategic guidance and leveraging their extensive network to support portfolio companies. Key team members include co-founders Gabriel Kra and Nathaniel Simons, and managing directors Mark Cupta and Matt Eggers. The team is based in San Francisco and is highly experienced in both investment and operational roles within the clean tech and sustainability sectors.

PreSeed Ventures, based in Kongens Lyngby, Denmark, is a prominent early-stage venture capital firm founded in 2000. The firm focuses on investing in startups within the life sciences, information technology, advanced manufacturing, and clean technology sectors, primarily in Denmark and Sweden. PreSeed Ventures has a diverse portfolio featuring companies like Trustpilot, an online review platform that went public in 2021, and Vivino, a popular online wine community platform. Other significant investments include Templafy, a template management platform, and Coinify, a crypto-based payment solution. The firm has also seen successful exits, such as Heyhack, acquired by F5 Networks, and Pento, a payroll automation service. The firm typically invests in seed and early-stage rounds, providing not only capital but also strategic support to help startups scale and achieve significant milestones. PreSeed Ventures is known for its commitment to fostering innovation and supporting ambitious entrepreneurs in building transformative companies.

Presight Capital, founded in 2019 by Christian Angermayer in partnership with Apeiron Investment Group, is a global venture capital firm based in West Hollywood, California. The firm manages over $600 million in assets across two early-stage funds and focuses on investing in biotechnology, consumer, fintech, deep tech, food tech, cryptocurrency, healthcare, and technology sectors. Notable investments by Presight Capital include ATAI Life Sciences, a mental health company using psychedelics; AbCellera, a biotech firm specializing in antibody therapies; and Compass Pathways, which focuses on mental health treatments using psilocybin. Other prominent companies in their portfolio are General Fusion, EnergyVault, and Perfect Day, which produces lab-grown dairy products. Presight Capital aims to support ambitious founders by providing capital, connections, and strategic advice. They invest in various stages, from seed to IPO, and have a diverse portfolio that includes companies like Razor Group, Syfe, and Alto Neuroscience. The firm's approach is characterized by a strong emphasis on transformative technologies and groundbreaking solutions across different industries​.

Previz Ventures is a tech and life sciences-focused early-stage venture capital firm founded in 2011 and headquartered in Herzliya, Israel. The firm invests into innovative technology companies addressing critical challenges in medical devices and healthcare information and communications technology, with a clearly defined entry point at post proof-of-concept, initial-to-approaching-commercial stage companies targeting large, underserved markets with scalable solutions. Previz concentrates overwhelmingly on Israeli-based companies to leverage the density of deep-tech talent in the Israeli ecosystem and the unique market access of its management team. The firm is led by founder and Managing Director Eliav Azulay Oz and operates with a small three-person team consistent with its selective, concentrated portfolio strategy. Previz has made approximately 8 disclosed investments and has a strong exit track record relative to its size. ReWalk Robotics (formerly Argo Medical) — a powered exoskeleton enabling paralyzed individuals to walk, stand, sit, and climb stairs — completed a NASDAQ IPO in September 2014 at an approximately $136 million market cap. Orpheus Medical, an enterprise clinical-video imaging platform, was acquired by Intuitive Surgical in February 2020. Clear-Cut Medical (intra-operative compact MRI for margin assessment of cancerous tissue) was among the firm's later disclosed investments. Previz screens investment candidates not only for financial return potential but for the transformative social value they can create in healthcare — improving patient outcomes, quality of life, and access to care. This dual mandate shapes the firm's portfolio construction: each company must meet a high bar on both clinical significance and commercial scalability. The firm provides ongoing strategic guidance across the full investment life cycle, from initial product development through regulatory clearance and downstream financing.

Primary Venture Partners, established in 2015 and headquartered in New York City, is a leading seed-stage venture capital firm focused on transforming startups into market leaders. The firm is co-founded by Brad Svrluga and Ben Sun, who have built a unique approach to venture investing that emphasizes high-conviction, low-volume investments with extensive operational support. Primary Venture Partners specializes in industries such as B2B SaaS, fintech, health tech, dev tools, and supply chain solutions. They are dedicated to New York City-based startups, leveraging their deep local network and resources to drive growth from seed to Series A and beyond. Their notable portfolio companies include Alloy, Alma, and Chief, each demonstrating their commitment to supporting groundbreaking technology and innovative business models. Primary differentiates itself with its "Primary Impact" team, which provides unparalleled support in areas like hiring, sales, and financial strategy. This team, often outnumbering the investors themselves, helps portfolio companies secure customers, build teams, and raise subsequent funding rounds, boasting a Series A success rate twice the industry average.

Prime Impact Fund is a $50 million venture capital fund dedicated to investing in transformative technology companies that aim to have a significant impact on climate change. Launched in 2018, the fund is an initiative of the Prime Coalition, an organization focused on unlocking catalytic capital to address climate challenges. Prime Impact Fund targets early-stage ventures with the potential for gigaton-scale emissions reductions, supporting high-risk, high-reward innovations that traditional capital sources often overlook. The fund's portfolio includes a wide array of companies working on cutting-edge technologies, such as Charm Industrial, which converts waste biomass into bio-oil for underground storage, and Lilac Solutions, which focuses on environmentally-friendly lithium extraction. The fund evaluates investments with rigorous attention to both techno-economic viability and climate impact, ensuring that each investment has the potential to drive substantial environmental benefits. Managed by Azolla Ventures, the Prime Impact Fund is driven by a diverse and experienced team, including Managing Directors Matthew Nordan, Dr. Johanna Wolfson, and Amy Duffuor, all of whom bring extensive backgrounds in technology and impact investing. The fund's unique structure, combining a nonprofit mission with a for-profit investment approach, allows it to maintain a strong focus on its goal of advancing a low-carbon economy.

Prime Movers Lab is a venture capital firm dedicated to investing in breakthrough scientific startups that have the potential to transform major industries and impact billions of lives. Their diverse portfolio includes notable companies such as Boom Supersonic, which is developing supersonic airliners, and Axiom Space, which aims to build the first commercial space station. Other significant investments include Quantum Space, Lyten, and Heliogen, showcasing their focus on innovative technologies in aerospace, energy, and sustainable materials​. Prime Movers Lab primarily invests in early-stage companies, often leading funding rounds with substantial checks that can range significantly based on the needs of the startup. Their investment strategy emphasizes deep scientific and technological advancements that offer solutions to global challenges. They seek out companies with the potential for high growth and significant impact, preferring those that demonstrate strong scientific foundations and transformative potential. The firm is based in Jackson, Wyoming, and operates with a mission-driven approach, looking to partner with visionary founders who are committed to pushing the boundaries of innovation. Key team members include Dakin Sloss, the founder and general partner, who has a robust background in supporting transformative startups. Amy Kruse, a general partner, leads life sciences investments with expertise in neuroscience and synthetic biology. Prime Movers Lab is known for its hands-on approach, providing not just capital but also strategic support, mentorship, and access to a network of industry experts. This approach helps their portfolio companies accelerate their growth and achieve their ambitious goals.

Primetime Partners is an early-stage venture capital firm based in New York, focusing on investing in startups that cater to the aging population. Founded in 2020 by Wall Street veteran Alan Patricof and wellness executive Abby Miller Levy, the firm aims to address the needs of older adults, a demographic expected to double to 1.6 billion by 2050. Primetime Partners' investment strategy revolves around seed and early-stage investments, typically ranging from $250,000 to $1 million. The firm focuses on sectors like healthcare, fintech, consumer products, and media, with the goal of improving the quality of life for older adults. Their portfolio includes companies that provide products and services in areas such as aging in place, financial security for retirees, and care management​. The firm also emphasizes supporting older entrepreneurs, recognizing the value of their experience and insights. Patricof and Levy bring a wealth of experience in both investment and operational roles, enhancing their ability to support portfolio companies beyond just financial investment​.

Privilege Ventures SA is a Swiss, FINMA-authorized early-stage venture capital firm founded in 2016 and headquartered in Lugano, Switzerland, with additional offices in Zurich and Boston. It is the venture capital arm of Privilege Management and is widely recognized as Switzerland's first female-led venture capital firm. The firm's investment thesis is grounded in a data-driven rationale: gender-mixed teams and women-led companies produce better financial outcomes, and Privilege frames this as an economic-return argument rather than a fairness one. The team of approximately ten people, including four Partners and two Venture Partners, spans Switzerland and Italy and brings deep expertise in entrepreneurship, management, finance, and governance. Privilege Ventures invests at seed and early-stage across three thematic pillars: healthtech, agrifood technology, and cleantech, with additional exposure to industrial tech, med-tech, wearables, and broader ICT. Its geographic footprint covers Switzerland and the rest of Europe, with selective Boston-based investments. The firm has approximately 40 portfolio companies. Notable names include Xsensio (wearable skin-chemistry monitoring, most recent disclosed investment March 2026), Adiposs (CHF 4 million Series A, June 2025), AgroSustain, Enantios, SONIX (May 2025), and SMEETZ (March 2025). Beyond capital, Privilege Ventures provides strategic support and mentorship throughout the investment lifecycle, with particular depth in helping portfolio companies navigate Swiss and European regulatory environments and institutional sales. Its status as Switzerland's first female-led VC has generated a differentiated LP base and a co-investor network that values diversity-aligned deal flow, creating a reinforcing pipeline advantage in sourcing and winning competitive seed rounds from underrepresented founding teams across the European life sciences and deep-tech ecosystem.

Procter and Gamble Ventures is the in-house startup studio of Procter and Gamble (NYSE: PG), the $80 billion-plus consumer-packaged-goods multinational. Founded in 2015 and operating from P&G's global headquarters in Cincinnati, Ohio, the studio was designed around a specific thesis: combine the agility of a startup with P&G's expertise, scale, and science to create genuinely new-to-the-world consumer brands targeting multi-billion-dollar categories of unmet need. P&G describes this as 'constructive disruption' — building new categories rather than new SKUs within existing ones. The studio develops both internal P&G-originated ideas and external founder-led ideas, embedding early-stage startups with P&G's R&D capabilities, brand marketing resources, supply chain, and global distribution network. Strategic verticals currently include pest control, lawn and garden, and pet parenting, with selective adjacencies in skincare and personal care. Portfolio and brand highlights include Zevo (people-friendly bug control — P&G Ventures' first major breakout, which reached $100 million in sales and became America's fastest-growing pest control brand), Spruce (pet and bee-safe weed killer, launched 2025), Opte (precision skincare device), Metaderm (skincare), Kindra (menopause care), and LoveIt. PitchBook and Crunchbase list approximately 8 disclosed investments. P&G Ventures' model is structurally distinct from traditional corporate venture: rather than making minority equity investments and remaining passive, the studio actively co-creates brands, funds their development, and manages their commercial launch using P&G infrastructure. This approach significantly de-risks the path from idea to shelf for early-stage consumer founders, but also means P&G retains significant operational control. For founders aligned with the consumer-goods category and seeking access to the world's largest CPG distribution network, the studio offers an unmatched commercial platform.

Procyon Ventures is a Cambridge, Massachusetts-based early-stage deep-tech venture capital firm founded in 2014, now operating under the First Star Ventures brand (firststar.vc) — Procyon Ventures I remains the legacy debut fund. The firm was co-founded by Drew Volpe (background in conversational AI, search, unstructured databases, computational biology, and blockchain) and Millie Liu (background in AI and machine learning analytics, and co-founder of Sequoia China-backed Infervision, an AI medical imaging company). The firm's articulated thesis is 'computing x real-world' — with concentration in techbio, climate, robotics, and industrial infrastructure, and legacy coverage spanning computational biotech, connected sensors, AR/VR, and blockchain. First Star primarily writes pre-seed, seed, and selective Series A checks. The firm is headquartered at 245 Main Street, Cambridge, Massachusetts. As of early 2025 the combined platform has made 48 disclosed investments across ten-plus years, including 4 investments in 2024 and 1 in 2025. Notable portfolio companies include Bedrock Energy (advanced geothermal heating and cooling with proprietary boring technology up to five times faster than conventional methods — Series A, January 2025), Plus One Robotics (pick-and-place warehouse robotics), Scoot Science (ocean and aquaculture data science), and Infinite Analytics. The Procyon/First Star team's technical depth — spanning conversational AI, biotech computation, and machine learning at the co-founder level — allows the firm to engage credibly with founders working on genuinely hard scientific and engineering problems. This hands-on scientific orientation is rare among early-stage VCs and positions the firm as a valued partner for researchers and technical founders who find conventional VC feedback lacking in domain rigor. The firm's Cambridge location provides direct access to MIT and Harvard's deep-tech research ecosystems.

Progression is the TikTok alumni fund. We write first checks in visionary consumer tech founders. Consumer tech is at the beginning of a Super Cycle driven by AI. We are investing in a new wave of founders who are building AI native products that are transforming the lives of everyday consumers.

Prolog Ventures is a U.S.-based venture capital firm that focuses on early-stage investments in health, wellness, and sustainability. With offices in St. Louis and San Francisco, Prolog has a strong track record of backing startups that promote healthier lives and a healthier planet. Notable investments include Plum Organics, a pioneer in organic baby food, and Benson Hill, an agricultural tech innovator. Their portfolio spans consumer health, agtech, and wellness products. Prolog Ventures primarily targets startups in North America, with a particular emphasis on business models that enhance well-being through innovative ingredients, products, and delivery mechanisms. Their partnership with Lonza extends their reach into functional foods, dietary supplements, and personal care. Prolog's strategy revolves around investing in visionary companies that align with their ethos of supporting healthy living. The firm prefers to get involved early, often leading rounds with check sizes ranging from $500K to $5 million. They value long-term partnerships and often leverage their deep network in healthcare and consumer products to help portfolio companies scale. The team is led by co-founders Greg Johnson, Brian Clevinger, and Ilya Nykin, all of whom bring decades of expertise in life sciences and venture capital.

Propel(x), co-founded by Swati Chaturvedi and Lisheng Wang, is an online investment platform that connects science and technology startups with accredited investors. The platform focuses on deep tech startups in sectors such as energy, green technology, aerospace, life sciences, IT, communications, industrial technologies, and financial services. Notable investments facilitated through Propel(x) include Brelyon, which develops immersive display technology with backing from Lockheed Martin and the E14 Fund, and BlockApps, an enterprise blockchain platform supported by Morgan Creek and Liberty City Ventures. Repurpose, a company working to reduce single-use plastics, is another example, with investors like Chaifetz Group and SWAT Equity Partners. Ligandal, a biotech firm specializing in regenerative medicine and pandemic defense technology, also raised capital on the platform with support from Y Combinator and Techstars. Propel(x) offers Special Purpose Vehicles (SPVs) to pool funds, allowing investors to meet higher investment minimums. This approach democratizes access to early-stage investments in groundbreaking technologies. The platform ensures comprehensive due diligence and curated deal flow, providing investors with well-vetted startups. Propel(x) has been recognized for making early investment opportunities accessible to a broader range of investors.

Prospect Venture Partners is a Palo Alto, California-based life-sciences venture capital firm founded in 1997 by Alex Barkas, Ph.D. and David Schnell, M.D., both formerly of Kleiner Perkins Caufield and Byers. Since inception, the firm has raised more than $1 billion of committed capital from foundations, endowments, pension funds, and other institutional limited partners across three flagship funds — Prospect Venture Partners I through III — making it one of the most established dedicated biomedical venture firms on the West Coast. The four Managing Partners are Alex Barkas, David Schnell, Russell Hirsch, M.S., Ph.D., and Jim Tananbaum, M.D., together representing decades of combined life-sciences venture experience. Prospect leads rounds and ultimately invests $10 million to $20 million per company across new-company incubations, first and second venture financings, and later-stage private and public expansion capital. The firm's mandate is commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies. Across its history, Prospect has recorded approximately 161 investments and 38 portfolio exits. Notable exits include Amira Pharmaceuticals (acquired by Bristol-Myers Squibb for $475 million in 2011) and Gloucester Pharmaceuticals (acquired by Celgene for $640 million in December 2009). The most recent disclosed exit was Nanosys in September 2023. Prospect's founding pedigree — two Kleiner Perkins partners building an independent life-sciences franchise in 1997 — gave the firm early access to the first generation of genomics and biotechnology companies and established LP and syndication relationships that have compounded over nearly three decades. Though the firm did not close a Fund IV and is not making new primary bets, its existing portfolio and governance roles continue to generate activity across its established base of biotech, pharma, and medical-device holdings.

Proxima Ventures is a Shanghai, China-headquartered healthcare-specialist venture capital firm founded in 2015. The firm's mission is to improve the health and lives of people worldwide by investing in emerging global healthcare technologies — with thematic concentration across biotechnology, novel therapeutics, medical devices, diagnostics, clinically significant digital healthcare solutions, advanced data analytics platforms, and innovative business models emerging from China's healthcare system reform. Proxima manages multiple funds denominated in both Chinese RMB and US dollars and is stage-agnostic within healthcare — deploying capital across angel, early, and growth-stage rounds with follow-on support through downstream financing. The firm is led by Founding Partner and Managing Partner George Li and Partner Haolin Sung. As of late 2025, Proxima Ventures has made approximately 105 disclosed investments, with consistent recent activity across surgical devices, drug discovery, and digital health. Notable recent deals include Shengxin Medical (surgical devices, most recent disclosed investment, November 2025), BridGene Biosciences (Series B-II, October 2025), Rapafusyn Pharmaceuticals (participated in a $28 million Series A in June 2024 — non-degrading molecular glue drug discovery), and Bioelectronica Corporation (co-invested with Co-win Ventures to accelerate pharmaceutical discovery and development). Proxima's team brings deep operating and investing experience in the life sciences industry alongside an extensive clinical and industrial network inside China. This local knowledge is a meaningful asset: China's healthcare system reform, aging population, and accelerating biotech research ecosystem create deal-flow dynamics and regulatory pathways that require genuine on-the-ground expertise to navigate. The firm's RMB-and-USD dual-currency structure allows it to invest efficiently across both domestic Chinese companies and internationally-oriented biotechs with China market ambitions.